Want to see ECOR full AI Analyst Report?
ECOR Stock Chart & Stats
$9.05
-$0.14(-2.26%)
At close: 4:00 PM EDT
$9.05
-$0.14(-2.26%)
Day’s Range― - ―
52-Week Range$4.41 - $12.70
Previous Close$6.05
Volume31.46K
Average Volume (3M)85.34K
Market Cap
$68.79M
Enterprise Value$80.77M
Total Cash (Recent Filing)$10.04M
Total Debt (Recent Filing)$9.56M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Oct 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding9,015,885
10 Day Avg. Volume85,004
30 Day Avg. Volume85,342
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)-22.29
Price to Sales (P/S)1.19
P/FCF Ratio-4.62
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit2.51
Enterprise Value/Ebitda-6.48
Forecast
1Y Price Target
$15.00Price Target Upside65.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$41.92M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue has increased across multiple reporting periods, indicating expanding commercial adoption of electroCore’s therapy platform. Continued top-line scaling can improve operating leverage over time, broaden the company’s market presence, and create a larger base from which to pursue eventual profitability.
High Gross MarginAn approximately 87% gross margin gives electroCore substantial economic value on each dollar of revenue before operating expenses. If revenue continues to scale, this margin profile could provide meaningful operating leverage and support reinvestment in commercialization, clinical programs, and distribution.
Governance RefreshThe leadership and governance refresh provides a more formalized operating structure, with the co-CEOs joining the board and updated bylaws defining the model. Shareholder approval of directors and executive compensation also indicates support for the revised leadership framework.
Bears Say
Persistent Operating LossesDespite strong gross margin, electroCore remains structurally loss-making because operating expenses continue to exceed gross profit. Persistent negative EBIT, net income, and EBITDA indicate that revenue growth has not yet translated into a self-sustaining earnings model.
Negative Cash GenerationThe company continues to consume significant cash in its operations rather than funding itself internally. Although the cash deficit improved versus 2025, ongoing negative operating and free cash flow leaves electroCore dependent on financing or additional resources to sustain investment and growth.
Leveraged Balance SheetNegative stockholders’ equity combined with materially higher debt has reduced financial flexibility and increased balance-sheet risk. With modest total assets of roughly $17.1M, further losses or funding needs could place greater pressure on liquidity and financing options.
Electrocore News
ECOR FAQ
What was Electrocore Llc’s price range in the past 12 months?
Electrocore Llc lowest stock price was $4.41 and its highest was $12.70 in the past 12 months.
What is Electrocore Llc’s market cap?
Electrocore Llc’s market cap is $68.79M.
When is Electrocore Llc’s upcoming earnings report date?
Electrocore Llc’s upcoming earnings report date is Oct 29, 2026 which is in 7 days.
How were Electrocore Llc’s earnings last quarter?
Electrocore Llc released its earnings results on Aug 06, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.422 by $0.092.
Is Electrocore Llc overvalued?
According to Wall Street analysts Electrocore Llc’s price is currently Undervalued.
Does Electrocore Llc pay dividends?
Electrocore Llc does not currently pay dividends.
What is Electrocore Llc’s EPS estimate?
Electrocore Llc’s EPS estimate is -0.27.
How many shares outstanding does Electrocore Llc have?
Electrocore Llc has 9,015,885 shares outstanding.
What happened to Electrocore Llc’s price movement after its last earnings report?
Electrocore Llc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.422. Following the earnings report the stock price went up 20.746%.
Which hedge fund is a major shareholder of Electrocore Llc?
Currently, no hedge funds are holding shares in ECOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electrocore Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (65.75% Upside)
$15.00 (65.75% Upside)
Blogger Sentiment
Bearish
ECOR Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth $101.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.90%
12-Months-Change
Fundamentals
Return on Equity
524.69%
Trailing 12-Months
Asset Growth
17.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Electrocore Llc
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
ECOR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong quarter of execution: record revenue, significant YoY growth, higher gross margins (87%), and meaningful improvement in adjusted EBITDA loss, all while reaffirming full-year guidance. Management also highlighted multiple catalysts (VA and DoD expansion, TruVega international launch, Quell OTC relaunch, R&D/clinical progress including PTSD work) and added experienced commercial leadership. Key risks discussed include a decrease in cash balances, Q1 seasonal cash burn and near-term capital timing, ongoing GAAP losses driven by nonrecurring charges, concentrated product penetration in the VA (only ~2.5%), and historically variable TACSTIM revenue. On balance, the positives around accelerating revenue, margin expansion, improving adjusted EBITDA, product and channel momentum, and clear operational priorities outweigh the near-term financial and execution risks presented on the call.View all ECOR earnings summariesECOR Stock 12 Month Forecast
Average Price Target
$15.00
▲(65.75% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
13.50% Insiders
2.89% Mutual Funds
4.26% Other Institutional Investors
76.82% Public Companies and
Individual Investors